aberrations and suit adequate to tolerate FCR therapy, should still be superior candidates for that latter, With all the advantage remaining this therapy may be completed in six months even though ibrutinib need to be taken indefinitely.It is important to look at the flow cytometry histograms to determine the intensity of expression and whether the